1. Home
  2. MGTX vs DLX Comparison

MGTX vs DLX Comparison

Compare MGTX & DLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$14.98

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Logo Deluxe Corporation

DLX

Deluxe Corporation

HOLD

Current Price

$24.42

Market Cap

1.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGTX
DLX
Founded
2015
1915
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
909.1M
1.1B
IPO Year
2018
1994

Fundamental Metrics

Financial Performance
Metric
MGTX
DLX
Price
$14.98
$24.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$24.57
$23.00
AVG Volume (30 Days)
1.1M
430.4K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
3.99%
EPS Growth
33.02
52.54
EPS
N/A
0.77
Revenue
$81,391,000.00
$2,133,200,000.00
Revenue This Year
$141.38
$1.35
Revenue Next Year
N/A
$1.30
P/E Ratio
N/A
$31.35
Revenue Growth
144.57
0.54
52 Week Low
$6.62
$15.41
52 Week High
$14.42
$32.07

Technical Indicators

Market Signals
Indicator
MGTX
DLX
Relative Strength Index (RSI) 78.12 53.59
Support Level $7.21 $22.04
Resistance Level N/A $24.70
Average True Range (ATR) 0.90 0.87
MACD 0.35 0.25
Stochastic Oscillator 91.10 81.27

Price Performance

Historical Comparison
MGTX
DLX

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

About DLX Deluxe Corporation

Deluxe Corp is principally a payments and data company. Its reportable segments are: Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment, which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services, as well as financial institution profitability reporting and business incorporation services.

Share on Social Networks: